iiinova — where your digital self keeps evolving

Reposted by Hannah R. Abrams

Larry Levitt @larrylevitt.bsky.social · 15/09/2026

New Census numbers show the number of people uninsured held steady in 2025. BUT...That's before enhanced ACA premium subsidies expired, causing millions of people to drop coverage this year. And before Medicaid cuts start to hit next year. www.census.gov/library/publ...

03919

Hannah R. Abrams @hannahrabrams.bsky.social · 12/09/2026

I learn something every time I read papers by oncology PharmDs. This @JCOOP_ASCO letter talks through discrepant findings between 2 studies of taxane titration. It would be great to save patients time-in-chair, but there are still some key concerns: ascopubs.org/doi/pdf/10.1...

020

Hannah R. Abrams @hannahrabrams.bsky.social · 09/09/2026

What's unique about financial toxicity in pediatric cancer settings? - Effect on siblings, costs of both food + babysitting for other kids & lost wages - Long-term financial effects for young families at a fragile time - Often using crowdfunding, eg GoFundMe, to help ascopubs.org/doi/pdf/10.1...

0134

Hannah R. Abrams @hannahrabrams.bsky.social · 24/07/2026

To a non-expert, this seems to be a neat new tool: Google can now create and export isochrones (maps of the space within a given travel time from a point) from a given point. Here's the space within 30 minutes of Seattle's trauma hospital (Harborview), for ex. developers.google.com/maps/documen...

Information page for Isochrones API.The Isochrones API calculates the area that a person can reach from a specific origin point within a set amount of time. Unlike a radius, which measures a straight-line distance, an isochrone accounts for actual road network travel times to create a polygon that represents true reachability.

Common use cases include:

Delivery logistics: Determine which customers are servable within 30 minutes of a warehouse.
Real estate: Find properties within a 45-minute commute of a workplace.
Urban planning: Analyze the accessibility of essential services like hospitals or grocery stores.
To get started, see Set up the Isochrones API.

30 minute isochrone for Harborview Medical Center

051

Reposted by Hannah R. Abrams

Larry Levitt @larrylevitt.bsky.social · 26/06/2026

New federal data shows that as of February, 19.2 million people were signed up for ACA plans, down about 3 million as enhanced premium subsidies were allowed to expire. That number will surely grow as more people find they can't pay much higher out-of-pocket premiums. aspe.hhs.gov/reports/aca-...

aspe.hhs.gov

ACA Exchange Enrollment in 2026

Key Points

0157

Hannah R. Abrams @hannahrabrams.bsky.social · 25/06/2026

Managing bone health in breast cancer survivors on aromatase inhibitors: comprehensive review out now in JCO OP! @jessicaallenmd.bsky.social ascopubs.org/doi/full/10....

010

Hannah R. Abrams @hannahrabrams.bsky.social · 22/06/2026

Nice editorial @thewonkologist.bsky.social & Dr. Nancy Keating about revisiting our priors re: Medicare Advantage for cancer care. While there is reason to be cautious and investigate, current data on MA vs traditional medicare in cancer is far from conclusive. ascopubs.org/doi/10.1200/...

142

Reposted by Hannah R. Abrams

Gabriele Mari @gmari.bsky.social · 16/03/2026

For unpaid #carers, earning more does not always lead to economic security. Motivated by the recent #Carer's #Allowance scandal, I have a new working paper @usociety.bsky.social on how much insecurity carers experience, for how long, who's most exposed and why: osf.io/preprints/so... 1/2

The figure shows reports of economic insecurity plotted against earnings from paid work. Earnings increase from left to right. At zero, earnings cross the Carer's Allowance limit of around 150 GBP per week. Past this limit, a carer loses eligibility for the allowance.

Carers who never report receipt of the allowance in the survey experience less and less insecurity when their earnings are higher.

For those with a history of benefit receipt, instead, insecurity doesn't decline smoothly. Arrears, the inability to save regularly, and money worries all spike past the earnings limit set by the allowance.

1129

Hannah R. Abrams @hannahrabrams.bsky.social · 22/06/2026

Does anyone know what happens if an entire group’s games all end in draws?

010

Hannah R. Abrams @hannahrabrams.bsky.social · 21/06/2026

Did not know cancer centers can technically now bill for patient navigation. I agree with the patients interviewed here: navigation is extremely high-value, and also I do not think it should be behind a paywall. ascopubs.org/doi/10.1200/...

220

Hannah R. Abrams @hannahrabrams.bsky.social · 20/06/2026

Waiting for clinical teams to order NGS slows down turnaround time by 2 weeks on average. It's time for insurance companies & cancer centers to work together & set up automatic pipelines in these situations, so patients don't have a long anxious wait to start treatment. ascopubs.org/doi/10.1200/...

Fig 2. (A) TAT intervals and definitions. (B) and (E) Yearly NSCLC CGP TAT and trend analysis (2018-2024). Boxes indicate median TAT, and whiskers indicate IQR. Dotted lines are linear trendlines: (B) overall TAT [Y = –1.154 × X + 2,361.0], (C) ordering TAT [Y = 0.2143 × X – 419.5], (D) specimen TAT [Y = –0.1357 × X + 279.0], and (E) molecular TAT [Y = –1.079 × X + 2,190.0]. P values reflect linear regression analysis (*P < .05, **P < .01, ***P < .001). CGP, comprehensive genomic profiling; NSCLC, non–small cell lung cancer; TAT, turnaround time.

011

Reposted by Hannah R. Abrams

Aaron Mitchell @thewonkologist.bsky.social · 18/06/2026

Timely, this recent piece in JCO Oncology Practice @ascocancer.bsky.social seems aimed towards helping private practice oncologists understand the implications of selling to their practice to PE firms: ascopubs.org/doi/10.1200/...

ascopubs.org

From Burnout to Buyout: Private Equity's Growing Appeal in Oncology | JCO Oncology Practice

132

Hannah R. Abrams @hannahrabrams.bsky.social · 18/06/2026

Midjourney has announced they're developing a full-body 60 second "ultrasonic CT". I want better & cheaper imaging. But the idea that: 50K scanners x 720 min x 30d = 1 billion scans/mo Seems totally unaware of supply/demand, logistical constraints of getting people in/out, & privacy concerns

100

Hannah R. Abrams @hannahrabrams.bsky.social · 03/06/2026

On the #ASCO26 hot topics of KRAS and toxicity: systematic review & meta-analysis in JCO OP of sotorasib dosing shows trend to improved PFS with LOWER dosing. Less toxicity -> longer time on-treatment? @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

050

Hannah R. Abrams @hannahrabrams.bsky.social · 30/05/2026

Key #desmoid tumor takeaways from RINGSIDE presentation (varegacestat) #ASCO26 #sarcoma today: - ORR 55.7%, remainder largely shrunk but under 30% - Quick time to pain improvement - only 4 weeks in many - 80% need for dose reduction primarily d/t diarrhea

010

Hannah R. Abrams @hannahrabrams.bsky.social · 30/05/2026

JCO OP at #ASCO26: Follow up yesterday's session, "Cancer Care in Times of Crisis and in Immigrant and Displaced Populations." Full case discussion out now @jco-asco.bsky.social: ascopubs.org/doi/10.1200/...

010

Hannah R. Abrams @hannahrabrams.bsky.social · 30/05/2026

#ASCO26 Abstract 12160: impressive effort to review charts of n = 848 patients for whether corticosteroids for irAE → worse cancer outcomes. Adds to/confirms existing literature in this area suggesting the concern is really with high doses.

Impact of corticosteroid exposure on long-term immune checkpoint in- hibitor responses in solid tumors. First Author: Theresa Medina, University of Colorado, Aurora, CO. Text beyond allowed length; summary: The steroid exposure was defined as very high if prednisone (or equivalent) ≥ 20mg/day and length of exposure was ≥ 42 days. 64.8% of patients experienced an irAE and 44.7% of patients developed G3-4 irAE requiring corticosteroids +/- steroid sparing agent. The low impact corticosteroid exposure did not affect PFS, OS or tumor specific survival. The very high impact CS exposure was associated with decrease in PFS (p = 0.02) but not with OS or TSS (p = 0.3). The high impact steroid sparing agent was associated with decrease in PFS (not significant) but the very high impact steroid sparing agent was associated with decrease in PFS. The chronic irAE was associated with slight improvement in PFS (not significant).

110

Hannah R. Abrams @hannahrabrams.bsky.social · 29/05/2026

What can we tell folks w/ taxane-induced peripheral neuropathy after early-stage cancer re: whether it will recover? @SWOG.org 1714, #ASCO26 abs 12117: - Of 1321 pts, 553 had TIPN at end of tx. - 48.5%, it improved - 33.8% didn't change - 17.7% worsened @drdawnhershman.bsky.social #survivorship

020

Hannah R. Abrams @hannahrabrams.bsky.social · 27/05/2026

Tips for fellows going to their first #ASCO26 (as I prepare to go to my whole of... second): Google "mccormick place floor plan" and pick your favorite version of the map to save to your phone. I'm sure the blue 3D one works for some people, but it does not for me! 😂

120

Hannah R. Abrams @hannahrabrams.bsky.social · 23/05/2026

It's not in your head: prior auth has increased over the past 10 years in oncology. (Though not as much as other specialties.) @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

120

Hannah R. Abrams @hannahrabrams.bsky.social · 21/05/2026

We have a lot of mechanisms to prevent OVER dosing of chemotherapy. This week in #JCOOP, Dr. Ruth Choa & colleagues outline a case in which an EMR error led a patient to receive an UNDER dose -only 50%- for 4/8 cycles of curative-intent treatment. @jco-asco.bsky.social ascopubs.org/doi/10.1200/...

Inadvertent Dose Reduction of Chemotherapy in a Patient Receiving Multiagent Neoadjuvant Chemotherapy
Authors: Ruth E. Choa, MD, PhD https://orcid.org/0000-0002-4798-7565 ruth_choa@dfci.harvard.edu, Kevin H. Lin, MD, PhD, Matthew L. Meizlish, MD, PhD https://orcid.org/0000-0002-4306-5061, Christof C. Smith, MD, PhD https://orcid.org/0000-0001-6517-0439, Katherine J. Feder, MD, MS, and Joseph O. Jacobson, MD, MSc

...AL elected to proceed with chemotherapy but was concerned about the acute toxicity of one of the agents. To accommodate these concerns, he and his oncologist decided on a modified regimen in which the agent is administered in divided doses, with half doses administered on days 1 and 2 rather than the full dose on Day 1. The intention was to use this split-dosing strategy for the first cycle, then resume standard chemotherapy for cycle 2 if the treatment was tolerated. However, day 2 of the order was accidentally deleted from the chemotherapy plan, and AL inadvertently received only half of the intended dose of the agent. Patient, provider, and pharmacy team all missed catching this error in the first cycle. Using the short-cut copy-forward function of the computerized prescriber order entry system (CPOE) of a proprietary electronic health record (EHR), the error was propagated forward for an additional 2 cycles until cycle 4 of the 8 planned cycles.

030

Hannah R. Abrams @hannahrabrams.bsky.social · 18/05/2026

340B as it exists now is crucial to oncology care. In JCO OP this month, @ascocancer.bsky.social releases updated policy recommendations for reform of the program: ascopubs.org/doi/10.1200/... @jco-asco.bsky.social

Title of article: 340B Drug Pricing Program: An Updated ASCO
Policy Statement

Authors:
Blase Polite, MD, MPP, FASCO 1 ; Niharika Dixit, MD 2 ; John Hennessy, BCPA 3 ; Marissa Rivera, MBA 4 ; Ashley Sumrall, MD, FACP, FASCO 5 ;
Wade Swenson, MD, MPH, MBA, FACP 6 ; Kashyap Patel, MD 7 ; Natalie Dickson, MD, MMHC, FACP 8 ; Jonathan Phillips, MPH 9 ;
Azam Masood, MPH 9 ; and Allyn Moushey, MSW 9

TABLE 2. ASCO Policy Recommendations for Reforming the 340B Drug Pricing Program
Changes to program eligibility
A new formula to determine 340B eligibility for non–hospital-af liated providers should be established. We suggest dividing the number of Medicaid,
uninsured, and dual-eligible patients by total patient visits (under a single TIN) to create a new measure known as the indigent care ratio
Independent oncology practices with multiple locations should be able to register a child site for the 340B Program as long as they bill under the same Tax ID
(TIN) as the eligible parent practice
ASCO supports reforms to ensure a covered entity’s right to engage multiple contract pharmacies. We recommend capping fees paid to contract
pharmacies and TPAs and establishing a civil monetary penalty for excessive fees
Transparency and accountability
Increase reporting and auditing requirements for 340B entities
Any institution accessing 340B discounts should be required to demonstrate they substantially meet the nancial assistance policy criteria outlined in IRS
501(r)
New civil monetary penalties (CMPs) should be broadened to include entities that fail to demonstrate transparency and adherence to requirements for
limiting patient nancial liability and directing savings back into direct patient care. Existing CMPs for manufacturers should remain in place and be
strengthened
End the exclusion of orphan drugs from 340B pricing for certain entities such as CAHs
Avoid narrowing the patient de nition to exclude insured patients and instead develop a de nition that would require the covered entity to have an ongoing
clinical relationship with the patient
Other nancial reforms
The HHS secretary or federal policymakers should either appropriate funds or implement other funding mechanisms to support reformed program oversight
and operations
Abbreviations: CAH, critical access hospitals; TPA, third-party administrator.

010

Reposted by Hannah R. Abrams

SurvivorshipIT @survivorshipit.medsky.social · 17/05/2026

#Biomarker data present in EHR were missing in 80%-100% of #FHIR extracts though demographic registry variables were highly concordant, highlighting gaps in real-world data extraction/exchange methods & risks of relying on RWD w/o validation academic.oup.com/jamiaopen/ar... #MedSky #OncSky #CanSky

academic.oup.com

Follow the data: tracking data quality and completeness in oncology real-world data

Lay Summary. Cancer research is rapidly evolving, with growing emphasis on genomic data and biomarker testing to guide treatments. In this study, we manual

042

Reposted by Hannah R. Abrams

Arrianna Marie Planey, PhD MA @arrianna-planey.bsky.social · 06/05/2026

I'd like to thank Reviewer #2 for asking why my colleagues and I bothered to assess cancer care-related financial toxicity among cancer survivors who were no longer in active treatment. That is, in fact, the period when the impacts are most felt.

1537

Reposted by Hannah R. Abrams

public health guy @publichealthguy1.bsky.social · 06/05/2026

honestly cure stories is a really hard space to work in because they take off so easily

011

Hannah R. Abrams @hannahrabrams.bsky.social · 06/05/2026

Genuine question for bluesky health info folks: Last month there were 2 pancreatic cancer studies shared, largely by press release: - RASolute 302, phase 3 study of 500 people, in which a daily pill DOUBLED survival for people whose cancer progressed after chemo - mRNA vaccine phase 1... (1/4)

181

Reposted by Hannah R. Abrams

Arrianna Marie Planey, PhD MA @arrianna-planey.bsky.social · 30/04/2026

Out now at Cancer Control: our qualitative study of the intersection of financial and travel burdens among rural-dwelling cancer survivors (who screened positive for financial toxicity)

doi.org

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

12011

Reposted by Hannah R. Abrams

Arrianna Marie Planey, PhD MA @arrianna-planey.bsky.social · 14/04/2026

When you read about applications of "AI" in medicine, a good Q to ask is "what is the billing code for that 'service'?" In the case of "screening" for IPV, no indication is required (unlike "assessments"). To document physical abuse, you can use ICD-10 code T74.1. Relevant source:

pmc.ncbi.nlm.nih.gov

The Measurement of Intimate Partner Violence Using International Classification of Diseases Diagnostic Codes: A Systematic Review

Intimate partner violence (IPV) is challenging to measure yet systematic surveillance of IPV is critical to informing public health prevention and response efforts. Administrative medical data provide...

1169

Hannah R. Abrams @hannahrabrams.bsky.social · 02/04/2026

CapeOx vs FOLFOX for adjuvant treatment in people w stage III colorectal #cancer & a diverting stoma: - ⬆️ hospitalizations, mostly GI effects (35% vs 18%) - ⬆️ rate of dose-reducing oxali (92% vs 40%) - ⬆️ diarrhea, mucositis, HFS 😨 mFOLFOX6 much better for QOL. #CRCSM ascopubs.org/doi/10.1200/...

ascopubs.org

Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma | JCO Oncology Practice

PURPOSEStandard adjuvant treatment for stage III colorectal cancer (CRC) combines intravenous oxaliplatin with a fluoropyrimidine, either with intravenous 5-fluorouracil with folinic acid…

020

Reposted by Hannah R. Abrams

Miranda Yaver @mirandayaver.bsky.social · 28/03/2026

This is especially important now that we're dealing with Medicaid paperwork requirements because it's so difficult to document gig work (which is disproportionately performed by Black and Hispanic workers, who are in turn more vulnerable to falling through the cracks and losing health coverage).

12611

Reposted by Hannah R. Abrams

Arrianna Marie Planey, PhD MA @arrianna-planey.bsky.social · 25/03/2026

NGL, I kinda did see "rural hospital closures" becoming a hot-button issue. The framing is already so polarized- crowding out similar focus on urban hospital closures (which also lead to bystander effects, e.g., crowding at surviving hospitals & worsen access for urban-dwelling communities of color)

251

Reposted by Hannah R. Abrams

Arrianna Marie Planey, PhD MA @arrianna-planey.bsky.social · 25/03/2026

Someone with a platform and a gift for policy/research translation needs to get ahead of this.

0114

Reposted by Hannah R. Abrams

Fumiko Ladd Chino, MD FASCO @fumikochino.bsky.social · 25/03/2026

“Will it work?” “I don't know… But we have a plan.” “I don't know” does not mean “I have nothing to offer.” It means “I will not pretend to know when I don't, and I will stand with you in the uncertainty.” Loved this @ascocancer.bsky.social #ArtofOncology by #radonc Dr Sondos Zayed

ascopubs.org

The Power of “I Don't Know”

2101

Reposted by Hannah R. Abrams

Michael D. Green, PhD @michaeldgreen.phd · 24/03/2026

Something that shouldn’t be lost is @drugmonkey.bsky.social highlighting these are training awards. Overall a devastating blow to the groups targeted. Not only were grants terminated (which shrinks the pool of people who can stay in science), a huge drop off in new awards also shrinks the pipeline.

1135

Reposted by Hannah R. Abrams

Pauline Funchain @funchainmd.bsky.social · 24/03/2026

Great learning on data science algorithms by Tina Hernandez-Boussard: when a predictive algorithm works @stanford-cancer.bsky.social but fails when used at @massgeneralbrigham.bsky.social because one hospital uses "Depends" to refer to an adult diaper and the other uses "depends" only as a verb...

media.tenor.com

a bald man is holding a hairless cat and the caption says it 's a homonym

ALT: a bald man is holding a hairless cat and the caption says it 's a homonym

021

Reposted by Hannah R. Abrams

Michael D. Green, PhD @michaeldgreen.phd · 24/03/2026

Infuriating story Future Dr. Jaramillo got a perfect score on his proposal. “Diversity” awards are scored w/ the same criteria as others. The new admin claims they are exchanging “DEI” for “merit”. In practice they are shutting down research mid-project even if they have the highest “merit”

"You're getting mixed signals as to what you represent, and the kind of work that you should be doing" said Jahn Jaramillo, a Ph.D. candidate at the University of Miami who recently published an analysis of the F31 awards that were terminated after his own grant was terminated. His grant, which had received a perfect peer review score, was on HIV in the Latino immigrant community. In some ways, the grant was squarely within the priorities of the Trump administration, which announced a plan in 2019 to end the HIV epidemic. Miami, where Jaramillo is based, is an area of high priority for that initiative. The work also felt particularly meaningful to Jaramillo, as a way to help communities he is part of.

But now, it feels as if his identities are being weaponized. "I was able to do that kind of community outreach work. You speak the language, you're very close to the community, so you're able to get research participants that perhaps had never engaged in research before," Jaramillo said.
But when his grant was terminated halfway through the project, he added, "you're disappointing them, you're confusing them.
That has long-term impacts with regards to them trusting research."

32912

Hannah R. Abrams @hannahrabrams.bsky.social · 24/03/2026

Should we be reserving stem cells for every patient with #myeloma treated with BCMA CAR T? Reduces severe infections by over half, but >4x cost. Need risk-stratification (or IVIG) to make sustainable. Cost effectiveness modeling in #JCOCCI : ascopubs.org/doi/10.1200/... @ziadbakouny.bsky.social

Title page and abstract:
Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma
Ehsan Malek, MD 1 ; Brian Betts, MD 1 ; Megan Herr, PhD 1 ; Marco Davila, MD 1 ; Shernan Holtan, MD 1 ; James J. Driscoll, MD, PhD 2,3 ; and Han Yu, PhD 1

FIG 3. Cost breakdown by strategy. Stacked bar chart of per-patient costs for the no-boost and boost
strategies. In the no-boost arm, all costs are attributable to hospitalization for infection. In the boost
arm, upfront reserve collection accounts for the majority of costs, while infection-related costs are
markedly lower. Total costs for each strategy represent the sum of upfront collection/storage fees
and longitudinal infection-related hospitalization costs. USD, US dollars.

Figure demonstrates cost per patient >$20,000 in boost group, under $5000 in no boost group. Majority of costs attributable to cost of stem cell collection up-front.

131

Hannah R. Abrams @hannahrabrams.bsky.social · 22/03/2026

This is cool: fullerenes, these neat carbon structures discovered in 1985 @ Rice University, significantly reduced incidence of radiation dermatitis in people with head & neck cancer getting radiation. Tx groups not perfectly matched, but encouraging study. ascopubs.org/doi/10.1200/...

010

Reposted by Hannah R. Abrams

Miranda Yaver @mirandayaver.bsky.social · 21/03/2026

This would be terrible. 99% of Medicare Advantage enrollees have prior authorization, a departure from how traditional Medicare has historically operated (though Oz is changing that), which causes delays and denials. What’s more, networks are often very limited, further reducing access to care.

12716

Hannah R. Abrams @hannahrabrams.bsky.social · 21/03/2026

Two important patient-perspective studies JCO OP @jco-asco.bsky.social this week: 1. What do people w/ advanced cancer participating in early-phase clinical trials (ie, Phase 1) understand about their prognosis? 27% believe cancer is curable 38% report never discussing prognosis w/ oncologist.

TABLE 2. Participant-Reported Measures: Prognostic Perceptions and
Hope at the Time of Phase I Clinical Trial Enrollment
27.4% report goal of cancer treatment is to cure cancer, 40% describe themselves as not terminally ill, and 37.8% report never or rarely discussing prognosis with oncologist.

110

Hannah R. Abrams @hannahrabrams.bsky.social · 16/03/2026

Broken incentives: when a $3K/year cancer treatment may cost patients more than a $200K/year one. 💸 Why isn't structured exercise getting the uptake it should? Follow up in @jco-asco.bsky.social on economics of #ChallengeTrial @csoncol.bsky.social ascopubs.org/doi/pdf/10.1...

Title: Economics of Translating Research Into Practice: The Case of
Exercise to Prevent Cancer Recurrence
Allan S. Detsky, MD, PhD 1,2,3 ; Kerry S. Courneya, PhD 4 ; Christopher M. Booth, MD 5 ; and Shivan J. Mehta, MD, MBA, MSHP 6,7

Finally, there is a distinct appeal of an exercise program for
patients and family members because of its effectiveness,
low toxicity, and broad accessibility. However, this appeal
depends on how it is paid for and framed. If they are faced
with direct costs because of the lack of insurance coverage,
they may never adopt it because people are price sensitive in
their health care purchase decisions. There is also the be-
havioral bias that patients and clinicians have toward drugs.
Through the availability heuristic, they may only see medical
therapies as helping in their ability to ght cancer. Thus,
they may not fully engage in exercise or be willing to pay
much out of pocket.
The results of the CHALLENGE trial have issued a challenge to
parties that fund and insure health care costs. Are they willing
to fund interventions beyond drugs, devices, and traditional
medical procedures that show comparable effectiveness and
are likely more economically attractive? The economic issues
related to this discovery raises a paradox: It may in fact be
easier to implement a new anticancer medicine with serious
side effects that costs $200,000 USD/year (where the pro t
motive, pathways to implementation and relationships be-
tween the interested parties are well known and previously
traveled) than a much more economically attractive program
of structured exercise proven to be effective in a rigorously
conducted large randomized trial that breaks new ground (ie,
shows an overall survival bene t). That is, it is easier to be
practice-changing than paradigm-changing.

021

Reposted by Hannah R. Abrams

Michal Horný @michalhorny.bsky.social · 12/03/2026

Cancer screenings are supposed to be provided at no cost to the patient, but way too often, patients receive medical bills for ancillary services. Those are medical services delivered solely because of screening but not classified as screening themselves (e.g., anesthesia for colonoscopy).

media.tenor.com

a woman says that seems silly with a netflix logo behind her

ALT: a woman says that seems silly with a netflix logo behind her

121